AU2005278962C1 - Isoindolin-1-one derivatives - Google Patents

Isoindolin-1-one derivatives Download PDF

Info

Publication number
AU2005278962C1
AU2005278962C1 AU2005278962A AU2005278962A AU2005278962C1 AU 2005278962 C1 AU2005278962 C1 AU 2005278962C1 AU 2005278962 A AU2005278962 A AU 2005278962A AU 2005278962 A AU2005278962 A AU 2005278962A AU 2005278962 C1 AU2005278962 C1 AU 2005278962C1
Authority
AU
Australia
Prior art keywords
mmol
nmr
substituted
phenyl
dihydroisoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005278962A
Other languages
English (en)
Other versions
AU2005278962A1 (en
AU2005278962B2 (en
Inventor
Alan H. Calvert
Bernard Thomas Golding
Roger John Griffin
Ian Robert Hardcastle
Per Kallblad
John Lunec
David R. Newell
Martin E. M. Nobel
Hendrika Maria Gerarda Willems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2005278962A1 publication Critical patent/AU2005278962A1/en
Application granted granted Critical
Publication of AU2005278962B2 publication Critical patent/AU2005278962B2/en
Publication of AU2005278962C1 publication Critical patent/AU2005278962C1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2005278962A 2004-09-02 2005-08-26 Isoindolin-1-one derivatives Expired AU2005278962C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419481.7A GB0419481D0 (en) 2004-09-02 2004-09-02 Isoindolin-1-one derivatives
GB0419481.7 2004-09-02
PCT/GB2005/003345 WO2006024837A1 (en) 2004-09-02 2005-08-26 Isoindolin-1-one derivatives

Publications (3)

Publication Number Publication Date
AU2005278962A1 AU2005278962A1 (en) 2006-03-09
AU2005278962B2 AU2005278962B2 (en) 2012-03-01
AU2005278962C1 true AU2005278962C1 (en) 2012-10-25

Family

ID=33155907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005278962A Expired AU2005278962C1 (en) 2004-09-02 2005-08-26 Isoindolin-1-one derivatives

Country Status (7)

Country Link
US (1) US8258175B2 (enExample)
EP (1) EP1786773B1 (enExample)
JP (1) JP5057273B2 (enExample)
AU (1) AU2005278962C1 (enExample)
CA (1) CA2578955A1 (enExample)
GB (1) GB0419481D0 (enExample)
WO (1) WO2006024837A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007228784B2 (en) * 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
CN101405285B (zh) * 2006-03-22 2012-10-10 詹森药业有限公司 作为mdm2和p53间相互作用的抑制剂的环状-烷基胺衍生物
WO2007139499A1 (en) * 2006-05-31 2007-12-06 Aprea Ab Compounds for use as a medicament
CN101605798A (zh) 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
SI2640467T1 (sl) 2010-11-19 2015-04-30 Novartis Ag Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
WO2013056015A1 (en) 2011-10-14 2013-04-18 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
TWI734715B (zh) * 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN107286074B (zh) * 2017-08-16 2019-08-20 厦门华厦学院 3-羟基异吲哚-1-酮衍生物及其制备方法
ES3067325T3 (en) 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
CN109053546B (zh) 2018-07-05 2021-04-27 中国科学院兰州化学物理研究所 一种苯酞类衍生物及其制备方法和应用
BR112021006647A2 (pt) 2018-10-08 2021-07-13 The Regents Of The University Of Michigan degradores de proteína mdm2 de pequenas moléculas
EP3659964A1 (en) 2018-11-28 2020-06-03 Hysilabs, SAS Catalysed process of production of hydrogen from silylated derivatives as hydrogen carrier compounds
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325066A (en) * 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
US3763178A (en) * 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
US4200759A (en) * 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) * 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
GB1601701A (en) * 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4331600A (en) * 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4505921A (en) * 1982-09-23 1985-03-19 Adir, S.A.R.L. Sulfonylurea compounds and their use in treating diabetes
US6344468B1 (en) * 1998-02-21 2002-02-05 Aventis Pharma Deutschland Gmbh Substituted isoindolones and their use as cyclic GMP modulators in medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466298A (en) * 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
AR203996A1 (es) * 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (enExample) * 1973-02-08 1976-04-09 Rhone Poulenc Ind
DE2840800C2 (de) * 1978-09-20 1980-02-14 Mannesmann Demag Ag, 4100 Duisburg Kanalbaumaschine
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
AU1466001A (en) * 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
KR100650966B1 (ko) * 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
JP2004217591A (ja) * 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
WO2005112932A2 (en) * 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763178A (en) * 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
GB1325066A (en) * 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
GB1601701A (en) * 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) * 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) * 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4331600A (en) * 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4505921A (en) * 1982-09-23 1985-03-19 Adir, S.A.R.L. Sulfonylurea compounds and their use in treating diabetes
US6344468B1 (en) * 1998-02-21 2002-02-05 Aventis Pharma Deutschland Gmbh Substituted isoindolones and their use as cyclic GMP modulators in medicaments

Also Published As

Publication number Publication date
AU2005278962A1 (en) 2006-03-09
CA2578955A1 (en) 2006-03-09
EP1786773A1 (en) 2007-05-23
GB0419481D0 (en) 2004-10-06
US8258175B2 (en) 2012-09-04
JP5057273B2 (ja) 2012-10-24
US20080261917A1 (en) 2008-10-23
EP1786773B1 (en) 2017-03-01
JP2008511601A (ja) 2008-04-17
AU2005278962B2 (en) 2012-03-01
WO2006024837A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
AU2005278962B2 (en) Isoindolin-1-one derivatives
RU2155187C2 (ru) Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
CA2766328C (en) Isoindolin-1-one derivatives
EP0673937B1 (en) Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
CA2598788C (en) Indoline-sulfonamides compounds
AU2002345644A2 (en) HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
JP5778297B2 (ja) 癌治療用のｈｄａｃ阻害剤としての新規４−アミノ−ｎ−ヒドロキシ−ベンズアミド
AU2002345644A1 (en) HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HU213605B (en) Process for producing amide composition and pharmaceutical compositions comprising same as active ingredient
BG109688A (bg) Карбоксиарил заместени дифенил уреи като инхибитори на raf киназа
GB2216517A (en) 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines
HK1203943A1 (en) Quinazolinedione derivative
US7750019B2 (en) Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
KR100686531B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
JPS609716B2 (ja) １，２―ベンズインチアゾリン―３―オン類、それらの製造法および医薬としての使用
JP6864124B2 (ja) キナーゼ阻害剤としてのピロロトリアジン誘導体
CN111763180A (zh) 苯并氮杂环类化合物及其制法和药物用途
CA2787860C (en) Substituted 2-imidazolidones and analogs and their use against cancer
US9365575B2 (en) Kinase inhibitors
US20250026741A1 (en) Inhibitors of the oncogenic shp2 phosphatase and uses thereof
JPH06220044A (ja) ベンズアミド誘導体
KR20240051859A (ko) Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
JPH07149722A (ja) 縮合複素環化合物、その製造法および剤
JPH059429B2 (enExample)
JPH0328425B2 (enExample)

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HARDCASTELE, IAN ROBERT; GOLDING, BERNARD THOMAS; CALVERT, ALAN H.; NOBEL, MARTIN E. M.; WILLEMS, HENDRIKA MARIA GERARDA; GRIFFIN, ROGER JOHN; LUNEC, JOHN; NEWELL, DAVID R. AND KALLBLAD, PER.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2012 .

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WILLEMS, HENDRIKA MARIA GERARDA; KALLBLAD, PER; HARDCASTLE, IAN ROBERT; GRIFFIN, ROGER JOHN; GOLDING, BERNARD THOMAS; LUNEC, JOHN; NOBEL, MARTIN E. M.; NEWELL, DAVID R. AND CALVERT, ALAN H. .

TH Corrigenda

Free format text: IN VOL 26 , NO 22 , PAGE(S) 2980 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS DELETE ALL REFERENCE TO 2005278962

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2012

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WILLEMS, HENDRIKA MARIA GERARDA; KALLBLAD, PER; HARDCASTLE, IAN ROBERT; GRIFFIN, ROGER JOHN; GOLDING, BERNARD THOMAS; LUNEC, JOHN; NOBEL, MARTIN E. M.; NEWELL, DAVID R. AND CALVERT, ALAN H.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired